Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepúlveda Sánchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Tannir NM, et al. Among authors: lee rj. JAMA Oncol. 2022 Oct 1;8(10):1411-1418. doi: 10.1001/jamaoncol.2022.3511. JAMA Oncol. 2022. PMID: 36048457 Free PMC article.
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Jonasch E, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425. N Engl J Med. 2021. PMID: 34818478 Free PMC article. Clinical Trial.
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK, Bauer TM. Meric-Bernstam F, et al. Among authors: lee rj. Clin Cancer Res. 2022 Apr 14;28(8):1540-1548. doi: 10.1158/1078-0432.CCR-21-2972. Clin Cancer Res. 2022. PMID: 35140121 Free PMC article. Clinical Trial.
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
Sonpavde GP, Maughan BL, McGregor BA, Wei XX, Kilbridge KL, Lee RJ, Yu EY, Schweizer MT, Montgomery RB, Cheng HH, Hsieh AC, Jain R, Grewal JS, Pico-Navarro C, Gafoor Z, Perschy T, Grivas P. Sonpavde GP, et al. Among authors: lee rj. Cancer Immunol Immunother. 2023 Mar;72(3):775-782. doi: 10.1007/s00262-022-03274-6. Epub 2022 Aug 23. Cancer Immunol Immunother. 2023. PMID: 35998004 Free PMC article. Clinical Trial.
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
Pond GR, Di Lorenzo G, Necchi A, Eigl BJ, Kolinsky MP, Chacko RT, Dorff TB, Harshman LC, Milowsky MI, Lee RJ, Galsky MD, Federico P, Bolger G, DeShazo M, Mehta A, Goyal J, Sonpavde G. Pond GR, et al. Among authors: lee rj. Urol Oncol. 2014 May;32(4):501-8. doi: 10.1016/j.urolonc.2013.10.007. Epub 2013 Dec 12. Urol Oncol. 2014. PMID: 24332646
1,200 results